Main Article Content


This study aimed to compare ciprofloxacin and cefotaxime exposure to develop ESBL producing Escherichia coli (E. coli). A total of 16 isolates of cefotaxime sensitive E. coli and ciprofloxacin were exposed to ciprofloxacin and cefotaxime for 14 days using the Kirby-Bauer antibiotic disc diffusion method. Colonies that grew on the edge of the inhibiting zone were exposed each day by the same method. Furthermore, we observed the occurrence of resistance to cefotaxime as ESBL screening test. Isolates were resistant, the following day the ESBL was confirmed by the Modified Double Disk Sinergy Test (MDDST) method using Cefotaxime (CTX), Ceftazidime (CAZ), Aztreonam (ATM), and Amoxilin Clavulanate (AMC) antibiotic discs. From 16 isolates of ESBL producing E. coli exposed to ciprofloxacin, it was obtained 4 (25%) to ESBL E. coli. ESBL production occurred after E. coli was exposed to ciprofloxacin on days 5, 6, 7, and 12. While those exposed to cefotaxime none becomes ESBL E. coli. There was no difference between ciprofloxacin and cefotaxime exposure to develop ESBL producing E. coli (p=0.101; Chi-square).


E. coli ESBL exposure of ciprofloxacin exposure of cefotaxime MDDST

Article Details

How to Cite
Amin, M., Wasito, E. B., & Triyono, E. A. (2020). Comparison between Exposure of Ciprofloxacin and Cefotaxime on Developing of Escherichia coli ESBL. Folia Medica Indonesiana, 56(2), 86–90.


  1. Babic M, Bonomo RA (2009). Mutation as a basis of antimicrobial resistance. Antimicrobial drug resistance mechanisms of drug resistance clinical and epidemiological aspects, 65-74
  2. Bush K (2009). The importance of B lactamases to the develoment of new B lactams. Antimicrobial drug resistance: mechanisms of drug resistance, clinical and epidemiological aspect, p 135-44
  3. CLSI M100S (2016). Performance standards for antimicrobial ausceptibility testing. Twenty-ourth Informational Supplement, 118-21
  4. Colodner R, Rock W, Chazan B, et al (2004). Risk factor for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients. Eur J. Clin. Microbiol Infect Dis., 163-7
  5. Dhillon RHP, Clark J (2012). ESBLs: A clear and present danger? Critical Care Research and Practice. Available at Accessed November 11, 2016
  6. Dolejska M, Villa L, Hasman H, Hansen L, Carottoli A (2013). Characterization of IncN plasmids carrying blaCTX-M-1 and qnr genes in Escherichia coli and Salmonella from animals, the environment, and humans. J. antimicrobe Chemother 68, 333-9
  7. Fortini D, Fashae K, Villa L, Feudi C, Fernandez AG, Carattoli A (2015). A novel plasmid carrying blaCTX-M-15 identified in commensal Escherichia coli from healthy pregnant women in Ibadan, Nigeria. Journal of Global Antimicrobial Resistance 3, 9-12
  8. Gallo G, Puglia AM (2014). Antibiotics and resistance: A fatal attraction. Antibiotics: Target, mechanisms, and resistance. Germany, Wiley VCH Weinheim, p 73-108
  9. Jacoby GA, Strahilevitz J, Hooper DC (2014). Plasmid mediated quinolone resistance. NIH Public Access. Available at Accessed December 5, 2016
  10. Kaur J, Chopra S, Sheevani, Mahajan G (2013). Modified double disc synergy test to detect ESBL production in urinary isolates of Escherichia coli and Klebsiella pneumoniae. Journal of Clinical and Diagnostic Research 7, 229-33
  11. Moodley A, Guardabassi L (2009). Transmission of IncN plasmids carrying bla CTX-M-1 between commensal Escherichia coli in pigs and farm workers. Antimicrob Agents Chemother 53, 1709-11
  12. Moudgal VV, Kaatz GW (2009). Fluoroquinlon resistance in bacteria. Antimicrobial Drug Resistance: mechanisms of Drug Resistance, Clinical and Epidemiological Aspect, 195-206
  13. Paramythiotou E, Routsi R (2016). Association between infections caused by multi drug resistant gram-negative bacteria and mortality in critically ill patients. World J Crit Care Med 5, 111-20
  14. Paterson DL, Bonomo RA (2015). Extended-spectrum ßactamases: a clinical update. CLIN. MICROBIOL. REV. 18, 657-86
  15. Talan DA, Takhar SS, Krishnadasan A, Abrahamian FM (2016). Fluoroquinolone-resistant and extended-apectrum ß-lactamase-producing Escherichia coli anfections in patients with pyelonephritis. United States, Emerging
  16. Sturenburg E, Mack D (2003). Extended-spectrum beta-lactamases: Implications for the clinical microbiology laboratory, therapy, and infection control. J. Infect. 47, 273-295
  17. Zeng X, Lin J (2013). Beta-lactamase induction and cell wall metabolism in Gram-negative bacteria. Available at Accessed October 20, 2016

Most read articles by the same author(s)